Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 12 | 2024 | 54 | 4.940 |
Why?
|
| Students, Pharmacy | 9 | 2024 | 63 | 2.850 |
Why?
|
| Anticoagulants | 5 | 2020 | 583 | 1.660 |
Why?
|
| Pharmacy | 4 | 2023 | 13 | 1.450 |
Why?
|
| Emotional Intelligence | 3 | 2024 | 13 | 1.240 |
Why?
|
| Pharmaceutical Services | 3 | 2023 | 35 | 1.170 |
Why?
|
| Faculty | 3 | 2023 | 100 | 1.040 |
Why?
|
| Analgesics, Opioid | 8 | 2024 | 397 | 1.040 |
Why?
|
| Pharmacists | 4 | 2023 | 83 | 1.020 |
Why?
|
| Schools, Pharmacy | 6 | 2023 | 22 | 0.920 |
Why?
|
| Curriculum | 5 | 2024 | 713 | 0.850 |
Why?
|
| Critical Care | 2 | 2018 | 647 | 0.790 |
Why?
|
| Hemodynamic Monitoring | 1 | 2021 | 12 | 0.740 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 256 | 0.740 |
Why?
|
| Social Desirability | 1 | 2020 | 18 | 0.720 |
Why?
|
| Thrombocytopenia | 2 | 2013 | 230 | 0.710 |
Why?
|
| Preceptorship | 1 | 2020 | 33 | 0.700 |
Why?
|
| Dicarboxylic Acids | 1 | 2020 | 34 | 0.690 |
Why?
|
| Pyridones | 2 | 2024 | 111 | 0.630 |
Why?
|
| Hypolipidemic Agents | 1 | 2020 | 176 | 0.630 |
Why?
|
| Pipecolic Acids | 2 | 2019 | 6 | 0.600 |
Why?
|
| Fatty Acids | 1 | 2020 | 338 | 0.600 |
Why?
|
| Stroke Volume | 1 | 2020 | 448 | 0.600 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 225 | 0.600 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2024 | 710 | 0.580 |
Why?
|
| Heart Rate | 1 | 2020 | 583 | 0.570 |
Why?
|
| Pyrazoles | 2 | 2024 | 301 | 0.560 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 548 | 0.550 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 33 | 0.470 |
Why?
|
| Codeine | 1 | 2014 | 24 | 0.470 |
Why?
|
| Pharmacy Residencies | 1 | 2013 | 5 | 0.450 |
Why?
|
| Propofol | 1 | 2014 | 44 | 0.450 |
Why?
|
| Cough | 1 | 2014 | 87 | 0.450 |
Why?
|
| Dexmedetomidine | 1 | 2014 | 44 | 0.440 |
Why?
|
| beta-Alanine | 1 | 2013 | 7 | 0.440 |
Why?
|
| Thrombin Time | 1 | 2013 | 4 | 0.440 |
Why?
|
| Morpholines | 1 | 2013 | 54 | 0.430 |
Why?
|
| Thiophenes | 1 | 2013 | 60 | 0.430 |
Why?
|
| Hypnotics and Sedatives | 1 | 2014 | 134 | 0.420 |
Why?
|
| Benzimidazoles | 1 | 2013 | 128 | 0.410 |
Why?
|
| Humans | 39 | 2024 | 122409 | 0.400 |
Why?
|
| Platelet Factor 4 | 1 | 2012 | 22 | 0.400 |
Why?
|
| Respiratory Tract Infections | 1 | 2014 | 263 | 0.380 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 453 | 0.370 |
Why?
|
| Leadership | 2 | 2024 | 226 | 0.370 |
Why?
|
| Antibodies | 1 | 2012 | 371 | 0.360 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 1022 | 0.360 |
Why?
|
| Educational Measurement | 3 | 2024 | 321 | 0.360 |
Why?
|
| Heparin | 1 | 2012 | 229 | 0.350 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 64 | 0.340 |
Why?
|
| Atrial Fibrillation | 4 | 2024 | 622 | 0.340 |
Why?
|
| Rivaroxaban | 2 | 2024 | 55 | 0.330 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 268 | 0.330 |
Why?
|
| Faculty, Pharmacy | 2 | 2020 | 6 | 0.320 |
Why?
|
| Opioid-Related Disorders | 2 | 2023 | 258 | 0.300 |
Why?
|
| Hydrocodone | 2 | 2019 | 35 | 0.300 |
Why?
|
| Medication Adherence | 2 | 2024 | 384 | 0.300 |
Why?
|
| Chronic Pain | 2 | 2019 | 119 | 0.290 |
Why?
|
| Intensive Care Units | 3 | 2018 | 475 | 0.280 |
Why?
|
| Heart Failure | 1 | 2020 | 2125 | 0.280 |
Why?
|
| Pain, Postoperative | 3 | 2024 | 253 | 0.280 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 1060 | 0.280 |
Why?
|
| Patient Discharge | 3 | 2024 | 487 | 0.260 |
Why?
|
| School Admission Criteria | 3 | 2023 | 21 | 0.250 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 1099 | 0.250 |
Why?
|
| Academic Performance | 1 | 2024 | 16 | 0.240 |
Why?
|
| Arginine | 2 | 2019 | 303 | 0.240 |
Why?
|
| Sulfonamides | 2 | 2019 | 259 | 0.240 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 88 | 0.230 |
Why?
|
| Markov Chains | 1 | 2024 | 80 | 0.230 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 104 | 0.230 |
Why?
|
| Life Change Events | 2 | 2023 | 59 | 0.220 |
Why?
|
| Community Pharmacy Services | 1 | 2023 | 10 | 0.220 |
Why?
|
| Mentoring | 1 | 2024 | 76 | 0.210 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 728 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 490 | 0.200 |
Why?
|
| Stroke | 2 | 2024 | 956 | 0.200 |
Why?
|
| United States | 7 | 2024 | 10475 | 0.190 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2022 | 68 | 0.190 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 13 | 0.190 |
Why?
|
| Physicians | 3 | 2023 | 582 | 0.190 |
Why?
|
| Pharmacies | 1 | 2020 | 13 | 0.180 |
Why?
|
| Controlled Substances | 2 | 2019 | 12 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 67 | 0.180 |
Why?
|
| Acute Pain | 1 | 2019 | 20 | 0.170 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 84 | 0.170 |
Why?
|
| Primary Prevention | 1 | 2020 | 162 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1025 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 355 | 0.160 |
Why?
|
| Minority Groups | 1 | 2020 | 250 | 0.160 |
Why?
|
| Aspirin | 1 | 2020 | 222 | 0.160 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 25 | 0.160 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 3305 | 0.150 |
Why?
|
| Warfarin | 1 | 2019 | 119 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2024 | 693 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 189 | 0.150 |
Why?
|
| Pandemics | 2 | 2023 | 1103 | 0.140 |
Why?
|
| Online Systems | 1 | 2016 | 12 | 0.140 |
Why?
|
| Interviews as Topic | 1 | 2018 | 365 | 0.140 |
Why?
|
| Hemodynamics | 1 | 2021 | 839 | 0.140 |
Why?
|
| Male | 12 | 2024 | 59575 | 0.130 |
Why?
|
| Problem-Based Learning | 1 | 2016 | 68 | 0.130 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2020 | 222 | 0.130 |
Why?
|
| Aged | 7 | 2024 | 18777 | 0.130 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 181 | 0.130 |
Why?
|
| Middle Aged | 9 | 2024 | 25586 | 0.130 |
Why?
|
| Pulmonary Embolism | 2 | 2019 | 172 | 0.130 |
Why?
|
| Adult | 10 | 2024 | 28743 | 0.120 |
Why?
|
| Enoxaparin | 1 | 2015 | 42 | 0.120 |
Why?
|
| Health Personnel | 1 | 2019 | 500 | 0.120 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 100 | 0.110 |
Why?
|
| Internet | 1 | 2016 | 369 | 0.110 |
Why?
|
| Specialization | 1 | 2014 | 75 | 0.110 |
Why?
|
| Delirium | 1 | 2014 | 47 | 0.110 |
Why?
|
| Dabigatran | 1 | 2013 | 25 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2014 | 62 | 0.110 |
Why?
|
| Female | 11 | 2024 | 64937 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2024 | 15878 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2020 | 828 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6302 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 180 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 383 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2014 | 291 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2013 | 158 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12036 | 0.100 |
Why?
|
| Hospitalization | 2 | 2019 | 1727 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 162 | 0.090 |
Why?
|
| Universities | 2 | 2022 | 124 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 815 | 0.090 |
Why?
|
| Students | 2 | 2023 | 246 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2014 | 996 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2013 | 384 | 0.080 |
Why?
|
| Length of Stay | 1 | 2014 | 1272 | 0.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 18 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1803 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1247 | 0.070 |
Why?
|
| Texas | 3 | 2019 | 3508 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2015 | 5970 | 0.060 |
Why?
|
| Inappropriate Prescribing | 1 | 2024 | 41 | 0.060 |
Why?
|
| Risk Factors | 2 | 2020 | 9868 | 0.060 |
Why?
|
| Social Responsibility | 1 | 2024 | 79 | 0.060 |
Why?
|
| Medicare Part C | 1 | 2024 | 35 | 0.060 |
Why?
|
| Time Factors | 1 | 2014 | 6176 | 0.060 |
Why?
|
| Decision Trees | 1 | 2023 | 48 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 237 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2023 | 117 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2013 | 2998 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2023 | 215 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 172 | 0.050 |
Why?
|
| College Admission Test | 1 | 2020 | 4 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2020 | 62 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2023 | 516 | 0.040 |
Why?
|
| Refuse Disposal | 1 | 2019 | 5 | 0.040 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 5 | 0.040 |
Why?
|
| Network Meta-Analysis | 1 | 2020 | 37 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 152 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 621 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 263 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 336 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 131 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 282 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 8805 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 199 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 3611 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 211 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 668 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2793 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2020 | 457 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2016 | 34 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 950 | 0.030 |
Why?
|
| Intention | 1 | 2016 | 94 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 136 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 4648 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1767 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 635 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1677 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 18971 | 0.020 |
Why?
|